tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2022 May 18.
doi: 10.1111/irv.13001. Online ahead of print.
Rapid influenza molecular testing in secondary care and influenza surveillance in England: Any impact?
Nicki L Boddington[SUP] 1 [/SUP], Suzanne Elgohari[SUP] 1 [/SUP], Joanna Ellis[SUP] 1 [/SUP], Matthew Donati[SUP] 1 2 [/SUP], Maria Zambon[SUP] 1 [/SUP], Richard G Pebody[SUP] 1 3 [/SUP]
Affiliations
Abstract
Introduction: The use of rapid molecular testing for influenza diagnosis is becoming increasingly popular. Used at the point of care or in a clinical laboratory, these tests detect influenza A and B viruses, though many do not distinguish between influenza A subtypes. The UK Severe Influenza Surveillance System (USISS) collects surveillance data on laboratory-confirmed influenza admissions to secondary care in England. This study set out to understand how rapid influenza molecular testing was being used and how it might influence the availability of subtyping data collected on influenza cases admitted to secondary care in England.
Methods: At the end of the 2017/2018 and 2018/2019 influenza seasons, a questionnaire was sent to all National Health Service Hospital Trusts in England to evaluate the use of rapid influenza testing. Surveillance data collected through USISS was analysed from 2011/2012 to 2020/2021.
Results: Of responding trusts, 42% (13/31) in 2017/2018 and 55% (9/17) in 2018/2019 used rapid influenza molecular tests, either alone or in combination with other testing. The majority of rapid tests used did not subtype the influenza A result, and limited follow-up testing occurred. Surveillance data showed significant proportions of influenza A hospital and intensive care unit/high dependency unit admissions without subtyping information, increasing by approximately 35% between 2012/2013 and 2020/2021.
Conclusions: The use of rapid influenza molecular tests is a likely contributing factor to the large proportion of influenza A hospitalisations in England that were unsubtyped. Given their clear clinical advantages, further work must be done to reinforce these data for public health through integrated genomic surveillance.
Keywords: influenza surveillance; rapid influenza testing; severe influenza.
. 2022 May 18.
doi: 10.1111/irv.13001. Online ahead of print.
Rapid influenza molecular testing in secondary care and influenza surveillance in England: Any impact?
Nicki L Boddington[SUP] 1 [/SUP], Suzanne Elgohari[SUP] 1 [/SUP], Joanna Ellis[SUP] 1 [/SUP], Matthew Donati[SUP] 1 2 [/SUP], Maria Zambon[SUP] 1 [/SUP], Richard G Pebody[SUP] 1 3 [/SUP]
Affiliations
- PMID: 35585686
- DOI: 10.1111/irv.13001
Abstract
Introduction: The use of rapid molecular testing for influenza diagnosis is becoming increasingly popular. Used at the point of care or in a clinical laboratory, these tests detect influenza A and B viruses, though many do not distinguish between influenza A subtypes. The UK Severe Influenza Surveillance System (USISS) collects surveillance data on laboratory-confirmed influenza admissions to secondary care in England. This study set out to understand how rapid influenza molecular testing was being used and how it might influence the availability of subtyping data collected on influenza cases admitted to secondary care in England.
Methods: At the end of the 2017/2018 and 2018/2019 influenza seasons, a questionnaire was sent to all National Health Service Hospital Trusts in England to evaluate the use of rapid influenza testing. Surveillance data collected through USISS was analysed from 2011/2012 to 2020/2021.
Results: Of responding trusts, 42% (13/31) in 2017/2018 and 55% (9/17) in 2018/2019 used rapid influenza molecular tests, either alone or in combination with other testing. The majority of rapid tests used did not subtype the influenza A result, and limited follow-up testing occurred. Surveillance data showed significant proportions of influenza A hospital and intensive care unit/high dependency unit admissions without subtyping information, increasing by approximately 35% between 2012/2013 and 2020/2021.
Conclusions: The use of rapid influenza molecular tests is a likely contributing factor to the large proportion of influenza A hospitalisations in England that were unsubtyped. Given their clear clinical advantages, further work must be done to reinforce these data for public health through integrated genomic surveillance.
Keywords: influenza surveillance; rapid influenza testing; severe influenza.